TY  - JOUR
T1  - EFfects of fda safety warnings may vary
AU  - Kuehn BM
Y1  - 2012/03/07
N1  - 10.1001/jama.2012.217
JO  - JAMA
SP  - 894
EP  - 895
VL  - 307
IS  - 9
N2  - 
Stacie B. Dusetzina, PhD, of the department of health care policy at Harvard Medical School in Boston, and a multi-institution team of colleagues examined the impact of FDA risk communications on health care use and found that the effectiveness of these messages depends on the type of recommendation, whether other effective therapies are available, and how often the messages were repeated (Dusetzina SB et al. Med Care. doi:10.1097/MLR.0b013e318245a160 [published online January 18, 2012]).

SN  - 0098-7484
M3  - doi: 10.1001/jama.2012.217
UR  - http://dx.doi.org/10.1001/jama.2012.217
ER  -